Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACTIL vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Major depressive disorder
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Primarily hepatic via CYP2D6 and other microsomal enzymes; active metabolite desmethylprotriptyline.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Approximately 90% bound, primarily to albumin and α1-acid glycoprotein.
~93% bound to plasma proteins, primarily albumin.
Vd approximately 8–15 L/kg, indicating extensive tissue distribution with higher CNS concentration than plasma.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Oral bioavailability approximately 30–40% due to first-pass metabolism (extensive hepatic cytochrome P450 biotransformation).
Oral: ~33% due to extensive first-pass metabolism.
For GFR <10 m L/min: use with caution and consider 50% dose reduction; no specific guidelines for GFR 10-50 m L/min.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Child-Pugh class B or C: reduce dose by 50-75%; avoid use in severe hepatic impairment.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Not recommended for children <12 years; for adolescents 12-18 years: 5-10 mg orally twice daily, max 60 mg/day.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Initiate at 5 mg orally twice daily; increase slowly with monitoring for orthostatic hypotension and anticholinergic effects.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Activation of mania/hypomania,Seizure threshold lowering,Cardiovascular toxicity (QT prolongation, arrhythmias),Angle-closure glaucoma,Urinary retention,Hepatic impairment,Concomitant MAOI use
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Hypersensitivity to protriptyline,Recent myocardial infarction,Concurrent MAOI therapy,QT prolongation or concomitant QT-prolonging drugs
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) if taking with MAOIs; however, protriptyline alone has no significant tyramine interaction. Grapefruit juice may increase protriptyline levels; avoid high intake. Alcohol can potentiate CNS depression. High-fiber foods may slightly reduce absorption; take at same time each day.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withdrawal, respiratory distress, tachycardia, and hyperirritability if used near term.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Present in breast milk; M/P ratio 0.5–1.9. Cases of drowsiness and poor feeding in infants reported; avoid breastfeeding or use with caution.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Decreased plasma concentrations due to increased volume of distribution; consider dose adjustment based on clinical response and serum levels; start at low dose and titrate.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
VIVACTIL (protriptyline) is a tricyclic antidepressant with a more activating profile; it has the fastest onset of weight gain among TCAs. It is often used for ADHD, narcolepsy, and depression with psychomotor retardation. Due to its long half-life (54-92 hours), dosing should be conservative in elderly. It has a high anticholinergic burden, risking urinary retention and cognitive impairment in older adults. Avoid in patients with recent MI or arrhythmias. Monitor EKG and drug levels in suspected overdose.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Take exactly as prescribed; do not stop suddenly as withdrawal may occur.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts or worsening depression immediately.,May cause dry mouth, constipation, blurred vision; use sugarless candy or gum for dry mouth.,Rise slowly from sitting or lying to prevent dizziness.,Do not take with MAOIs or within 14 days of stopping them.,Notify doctor if you experience fast/irregular heartbeat, difficulty urinating, or seizures.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VIVACTIL vs FLEXERIL, answered by our medical review team.
VIVACTIL is a Tricyclic Antidepressant that works by Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIVACTIL and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIVACTIL is: 10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIVACTIL and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIVACTIL is classified as Category C. First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withd. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.